Several studies revealed that 25–300 mg/kg EGCG attenuated CCl4-induced liver fibrosis partially through inhibiting HSC activation and targeting MMP-2 via the modulation of membrane type 1-MMP activity [172]. The gene discussed is MMP2; the disease is Hepatic fibrosis.